Prediction of pancreatic cancer risk and therapeutic response with next-generation sequencing

[...]this is yet another study supporting the role of immune inhibitors in pancreatic cancer, highlighting the potential targetability of the immunogenic PDA subclass, characterized by CTLA4 and PD1 pathway upregulation (4). The basic research aim to complete the list of CDGs and CPGs with whole-exo...

Full description

Saved in:
Bibliographic Details
Published in:Biomarkers in medicine 2018-01, Vol.12 (1), p.5-8
Main Authors: Kyrochristos, Ioannis D, Ziogas, Demosthenes E, Glantzounis, Georgios K, Roukos, Dimitrios H
Format: Article
Language:English
Subjects:
Biomarkers
Biomarkers - metabolism
Biopsy
Breast cancer
Classification
Clinical trials
Cloning
Consortia
CTLA-4 protein
Deoxyribonucleic acid
Diabetes
DNA
DNA sequencing
Environmental factors
Genomes
High-Throughput Nucleotide Sequencing - methods
Humans
Immunogenicity
International organizations
intratumor heterogeneity
Invasiveness
Medical prognosis
Metastasis
Mutation
Next-generation sequencing
NMR
Nuclear magnetic resonance
Ovarian cancer
Pancreatic cancer
Pancreatic Neoplasms - genetics
Pancreatitis
Patients
PD-1 protein
prediction
Prevention
Prostate
RNA sequencing
Sequence Analysis, RNA - methods
Surgical outcomes
Therapeutic applications
Tumors
whole-genome sequencing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]this is yet another study supporting the role of immune inhibitors in pancreatic cancer, highlighting the potential targetability of the immunogenic PDA subclass, characterized by CTLA4 and PD1 pathway upregulation (4). The basic research aim to complete the list of CDGs and CPGs with whole-exome sequencing (WES) and WGS raises the opportunity not only to discover novel oncotargets but also to use them at very low cost for targeted next-generation sequencing (tNGS). [...]the completion of these catalogs raises new opportunities for screening high-risk individuals who meet the criteria of both exposure to established environmental factors and harboring identified CPGs. [...]the noninvasive identification of circulating genomic subclones (cGSs) by sequencing plasma cell-free DNA (cfDNA-NGS), before and after therapeutic interventions, as well as over the disease course, offers unprecedented clinical potential. According to current guidelines, no histopathological diagnosis is suggested before surgical resection in most cases, while invasive EUS-fine-needle aspiration (EUS-FNA) biopsy is associated with complications (5).
ISSN:1752-0363
1752-0371
DOI:10.2217/bmm-2017-0315